BSEInsider Trading / SAST3d ago · 30 Sept 2026, 05:39 pm

Closure of Trading Window

Natco Pharma Ltd · 524816

✦ AI SummaryMgmt Change

Natco Pharma Ltd has announced the closure of its trading window for directors, designated persons, and their relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natco Pharma Ltd - 524816 - Closure of Trading Window

Attachments (1)

📄

028c6254-ed68-433b-bf87-01d26dc4fbdb.pdf

pdf

Download →
View document text
30th September, 2026 M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Closure of Trading Window We wish to inform you that the Trading Window for dealing in the securities of the Company would remain closed for the Directors, Designated Persons, their immediate relatives and all other connected persons covered in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, with effect from October 1, 2026 to till 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter ending September 30, 2026. The date of the Board Meeting for declaration of the unaudited financial results of the Company for the quarter ending September 30, 2026 will be intimated in due course of time. Thanking you Yours faithfully For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer